Venture Capital Investment | Plutus Investment Group
About Us
A team of industry experts with a successful investment experience
Our Philosophy
Investing in Tomorrow’s Champions
Founded in 2021 by a seasoned group of entrepreneurs, investors and industry veterans, Plutus Investment Group is a family office that focuses on backing startups in Europe and the USA.
We’re looking for leaders with a drive and a strong vision. While we only invest in a handful of companies a year, it means we can provide the time, the energy and the capital for those companies to succeed and become a game changers
About
Our Management Team
Member Name
Member Position
Member Description
Our team and board combined investment experience exceeds 180 years
MOHAMMED JAMAL
Founder – Chief Executive Officer & Board Chairman
Bio
Mr Jamal has over 18 years of experience in structuring, placement, trading, private equity and liquid Investing. Mr Jamal started his career at Morgan Stanley in the structured credit team in 2003. In 2009 Mr Jamal moved to Resource America a $15Bn credit fund to lead their business in Europe.
In 2012 Mr Jamal founded Molton Street Capital a London based CLO, CDO and ABS trading company that traded over $3Bn.
In 2016 Mr Jamal co-founded Forepont Capital Group, a leading life science Venture Capital fund with office in London, New York and Paris
Mr Jamal invested in more than 20 companies since 2012 and made multiple successful exits.
Mr Jamal holds a Masters degree in Applied Mathematics and Computer Sciences from Ecole Centrale Paris (top French “ Grande Ecole” ) and an advanced degree (DEA) in Finance and Economics from La Sorbonne University in Paris.
PRASHANT MORI
Chief Operating Officer, Chief Scientist & Board Member
Bio
An Entrepreneur, Drug Discovery & Diagnostic Research Scientist with 19 years of proficiency in biopharma and drug R&D, on numerous drug targets including New Chemical Entity & New Biological Entity at various stages. Thus, possess a comprehensive understanding of various processes involved in drug research, discovery, development, leading to pre-clinical stages. An avid Artificial Intelligent proponent, he is an expert in Molecular Biology, Biochemistry and Biophysics. Worked with TCR based Immunotherapy when the technology was in infant stage at Avidex (Now Immunocore & Adapimmune ) and other programs in laboratory which is now successfully marketed drugs in the market (Bimekizumab – UCB Pharma). Discovered novel way to decipher PPI for designing drug like molecules for TNF modulation to integrate the idea in drug development program which was partnered with Sanofi for multi million pounds and profit-sharing deal, on achievable milestones. He has lead teams, to set-up and manage small businesses, communal laboratories, besides supporting and expanding family’s Salt, Mining & Commodities businesses internationally. Multifaceted persona with culmination of science and business, Prashant brings on board lateral thinking to solve technical problems and help expand Biopharma, Diagnostics & AI based businesses.
ISSAM EL MOUHTADI
Head of Business
Development
Bio
M. El Mouhtadi has started his career in London in 2005 at Goldman Sachs as a research analyst covering the European banking sector before becoming an entrepreneur in 2010 in Morocco & UAE. He founded and successfully built several companies throughout the years in the distribution, chemicals and special civil engineering technology, with innovation and technology being at the core of each endeavor. M. El Mouhtadi brings in an extensive network across the MENA region and with his hands-on approach he has developed a strong expertise around business structuring, value creation, technical know-how and business development that brings a bottom-up and a value creation expertise to Plutus investments. Furthermore, M. El Mouhtadi brings in an extensive network across the MENA region.
M. El Mouhtadi holds a Masters degree in Science of Management (Msc.), with a major in Finance from EM Lyon Business School (Top French. “Grande Ecole”).
The Geniuses Behind Our Work
Board Members
Member Name
Member Position
Member Description
We have an outstanding Board Of Directors with an extended expertise in key industries
MOHAMMED JAMAL
Chief Executive Officer & Chairman (London)
Bio
Mr Jamal has over 18 years of experience in structuring, placement, trading, private equity and liquid Investing.
Mr Jamal started his career at Morgan Stanley in the structured credit team in 2003. In 2009 Mr Jamal moved to Resource America a $15Bn credit fund to lead their business in Europe.
In 2012 Mr Jamal founded Molton Street Capital a London based CLO, CDO and ABS trading company that traded over $3Bn.
In 2016 Mr Jamal co-founded Forepont Capital Group, a leading life science Venture Capital fund with office in London, New York and Paris
Mr Jamal invested in more than 20 companies since 2012 and made multiple successful exits.
Mr Jamal holds a Masters degree in Applied Mathematics and Computer Sciences from Ecole Centrale Paris (top French “ Grande Ecole” ) and an advanced degree (DEA) in Finance and Economics from La Sorbonne University in Paris.
DR HITESH BODANI
Co-Chairman Board (London)
Bio
Dr. Hitesh Bodani, Chairman, is a seasoned and visionary entrepreneur with over two decades of diverse experience across hospitality, real estate, medical technology, and mining sectors. Throughout his illustrious career, Hitesh has demonstrated exceptional leadership in translating bold visions into tangible corporate realities. He has pioneered trading solutions for internationally recognized brands, facilitated wholesale delivery of top-brand products in Africa, the Middle East, and Asia, and contributed significantly as a board member at Fortune Group, Dubai, overseeing luxury projects of significant scale. Notably, his ventures in UK real estate under Fortress Group have included the successful development and exit of Premier Inn hotels, alongside other prominent projects like residential conversions and strategic acquisitions. As a board adviser to Direct Opportunities Network, Hitesh plays a pivotal role in fostering global growth opportunities and fundraising endeavors, utilizing his extensive network of influential contacts. Beyond his entrepreneurial pursuits, Hitesh is deeply committed to philanthropic causes, supporting Vision Africa and playing a crucial role in establishing a UK government-approved Covid testing and blood testing medical laboratory during the pandemic. His mining ventures in East Africa further underscore his dedication to sustainable development and economic empowerment. Dr. Bodani’s entrepreneurial journey embodies innovation, resilience, and a steadfast commitment to driving positive change across industries and communities worldwide.
LAILA SAMADY-MUSTAD, PhD
Venture Partner – Life Science (London)
Bio
Laila is a scientist, advisor, entrepreneur and investor with more than 25 years’ experience academically and in the pharmaceutical, medical and biotechnology industry in the UK, US and France. Her expertise is in medical affairs, partnerships, business development and capital raising strategies.
Based in London, she is a Venture Partner, Advisor and Member of the Investment Committee at Ryse Asset Management, a Health Technology investment firm. She is a Venture Partner at Plutus Investment Group, a Family Office focused on early stage and late stage companies in Europe and US. Laila is also a Director and Partner at Pannexus, a consultancy firm specialising in business development, marketing and international trade opportunities for companies in Europe and US, within the sectors of retail and government.
Previously, she was Chief Scientific Officer and Member of the Board of Directors for Vigilent Labs, a digital health company focused on providing an end-to-end testing solution, a “Lab In Your Hand” with near real-time surveillance of diseases. She was Vice-President, Business Development for Covanos Inc., a development stage medical technology company focusing on computational heart and vascular diagnostics and Vice-President, Business Development for G3 Therapeutics, a biotechnology company with expertise in life sciences, artificial intelligence and data computing. While at Boehringer Ingelheim, she served in increasingly senior roles in Washington DC and London, leading to Global Partnerships in Oncology.
With a PhD in Molecular Pathology and Immunology from University College London (UCL), her work at UCL led to the development of patents and a spin out company, BioVex, acquired by Amgen in 2011 for $1B. Prior to her PhD, Laila obtained a BSc in Biochemistry at Trinity College, Hartford, CT, US and an MSc / DEA in Molecular and Cell Biology from Institut Pasteur.
JAMAL BUTT, FRPharmS
Venture Partner – Bio-Pharma & Med. Devices (London)
Bio
Jamal is a seasoned healthcare leader with over 25 years of experience in healthcare service transformation, digital technology innovation, life science start ups and commercial operations. He is currently the Entrepreneur in Residence at Cambridge University, where he supports and promotes the commercialisation of life changing innovation via spin-out companies. He was previously the CEO of MedAdvisor UK, one of the world’s largest SaaS platforms for medication management and digital adherence programmes.
He also contributes to the healthcare sector as a Fellow of the Royal Pharmaceutical Society, a Non-Executive Director at Croydon Health Services NHS Trust, and a Chair of the Croydon Health Charity Committee. He holds several Non Executive Director positions for digital start-ups from Cambridge University.
He was previously on the pharmacy boards of both Boots UK and LloydsPharmacy UK, where he led the operations and service innovation teams, including introducing out-sourced out patient dispensaries into the UK. He holds a Bachelor of Pharmacy from UCL and a certificate in Digital Disruption Models from Cambridge Judge Business School. He also studied Finance and Management at Oxford University Said Business School, and AI transformation at Imperial Business School. He is a strong advocate for integrated and patient-centric healthcare solutions that improve outcomes and efficiency.
PRASHANT MORI
COO & Board Member
Bio
An Entrepreneur, Drug Discovery & Diagnostic Research Scientist with 19 years of proficiency in biopharma and drug R&D, on numerous drug targets including New Chemical Entity & New Biological Entity at various stages. Thus, possess a comprehensive understanding of various processes involved in drug research, discovery, development, leading to pre-clinical stages. An avid Artificial Intelligent proponent, he is an expert in Molecular Biology, Biochemistry and Biophysics. Worked with TCR based Immunotherapy when the technology was in infant stage at Avidex (Now Immunocore & Adapimmune ) and other programs in laboratory which is now successfully marketed drugs in the market (Bimekizumab – UCB Pharma). Discovered novel way to decipher PPI for designing drug like molecules for TNF modulation to integrate the idea in drug development program which was partnered with Sanofi for multi million pounds and profit-sharing deal, on achievable milestones. He has lead teams, to set-up and manage small businesses, communal laboratories, besides supporting and expanding family’s Salt, Mining & Commodities businesses internationally. Multifaceted persona with culmination of science and business, Prashant brings on board lateral thinking to solve technical problems and help expand Biopharma, Diagnostics & AI based businesses.
RADOUANE OUDRHIRI PhD
Head of Information Technology & Artificial Intelligence (London)
Bio
Dr. Radouane has an extensive experience in leading world-class software and data-intensive system developments in different industries from Telecom to Healthcare, Nuclear, Automotive, Financials. Expert in IT and software architecture, design, quality engineering and sits as Scientific or Technology advisor on the board of multiple technology companies. He is involved in starting the organisations from scratch, building, growing, and improving the value and performance of from seed stage to large corporates.
Lecturer at various European universities and Engineering schools, on Innovation, Information Systems and software engineering he is evaluator with the European Commission information technology directorate. A regular conference speaker on Software Quality Engineering, Six Sigma and DFSS for IT and Software development he possesses proficiency in computer systems validation and compliance in pharmaceuticals and related life-sciences.
A Fellow of the Royal Statistical Society (RSS) and member of the ISO Technical Committee (TC69: Applications of Statistical methods) Radouane has co-authored the Lean & Six Sigma Standard (ISO 18404) as well as the new standard under development (Design for Six Sigma) besides being a part of the newly formed international Group on Big Data (nominated by BSI as the UK representative/expert), he was recently nominated as the Convenor of the working group on Design of Experiments.
ISSAM EL MOUHTADI
Board Member
Bio
M. El Mouhtadi has started his career in London in 2005 at Goldman Sachs as a research analyst covering the European banking sector before becoming an entrepreneur in 2010 in Morocco & UAE. He founded and successfully built several companies throughout the years in the distribution, chemicals and special civil engineering technology, with innovation and technology being at the core of each endeavor. M. El Mouhtadi brings in an extensive network across the MENA region and with his hands-on approach he has developed a strong expertise around business structuring, value creation, technical know-how and business development that brings a bottom-up and a value creation expertise to Plutus investments. Furthermore, M. El Mouhtadi brings in an extensive network across the MENA region.
M. El Mouhtadi holds a Masters degree in Science of Management (Msc.), with a major in Finance from EM Lyon Business School (Top French. “Grande Ecole”).